Molecular markers of endometrial carcinoma detected in uterine aspirates

@article{Cols2011MolecularMO,
  title={Molecular markers of endometrial carcinoma detected in uterine aspirates},
  author={Eva Col{\'a}s and Cristina P{\'e}rez and Silvia Cabrera and N{\'u}ria Pedrola and Marta Monge and Josep Castellv{\'i} and Fernando Eyzaguirre and Jesus Gregorio and Anna Ruiz and Marta Llaurad{\'o} and Marina Rigau and Marta Laguna Garc{\'i}a and T Ertekin and Melania Montes and Rafael L{\'o}pez-L{\'o}pez and Ram{\'o}n Carreras and Jordi Xercavins and Alicia Ortega and Tamara Maes and Elisabet Rosell and Andreas Doll and Miguel Abal and Jaume Reventós and Antonio Gil-Moreno},
  journal={International Journal of Cancer},
  year={2011},
  volume={129}
}
Endometrial cancer (EC) is the most frequent of the invasive tumors of the female genital tract. Although usually detected in its initial stages, a 20% of the patients present with advanced disease. To date, no characterized molecular marker has been validated for the diagnosis of EC. In addition, new methods for prognosis and classification of EC are needed to combat this deadly disease. We thus aimed to identify new molecular markers of EC and to evaluate their validity on endometrial… 

Molecular diagnosis of endometrial cancer from uterine aspirates

Rapid and reliable diagnosis of endometrial cancer (EC) in uterine aspirates is highly desirable. Current sensitivity and failure rate of histological diagnosis limit the success of this method and

Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers

This approach provides the first evidence of the high intra-tumor genetic heterogeneity associated with endometrial cancer, evident when multiple regions of tumors are analyzed from an individual hysterectomy, and captures this heterogeneity, solving the potential problem of incomplete genetic characterization when a single tumor biopsy is analyzed.

Identification of early stage recurrence endometrial cancer biomarkers using bioinformatics tools

The targeting protein for Xklp2 (TPX2) was the most promising independent prognostic biomarker in stage I EC, and further validation studies in larger and independent EC cohorts will contribute to confirm the prognostic value of TPX2.

Biomarkers in endometrial cancer: Possible clinical applications (Review).

Studies of genes with abnormal expression in endometrial cancer have identified multiple oncogenes, tumor suppressors, mismatch repair genes, apoptosis-associated genes, levels of hormone receptors and DNA ploidy and aneuploidy as biomarkers of endometrium cancer.

An eleven autophagy-related genes-based prognostic signature for endometrial carcinoma

An eleven-ARG signature was established, which was probably effective in the prognostic prediction of patients with EC and suggested good value for clinical utility.

High-Risk Endometrial Carcinoma Profiling Identifies TGF-β1 as a Key Factor in the Initiation of Tumor Invasion

It is shown that the characterization of the molecular changes associated with the acquisition of an aggressive phenotype represents a realistic strategy for the rational identification and characterization of new potential therapeutic targets in an effort to improve the clinical management and the outcome of high-risk endometrial cancer patients.

Loss of RKIP expression during the carcinogenic evolution of endometrial cancer

It is demonstrated for the first time that RKIP expression is lost during the carcinogenic evolution of endometrial tumours and that the loss of RKip expression is associated with a malignant phenotype.

Therapeutic Discovery High-Risk Endometrial Carcinoma Profiling Identifies TGF-b 1 as a Key Factor in the Initiation of Tumor Invasion

It is shown that the characterization of the molecular changes associated with the acquisition of an aggressive phenotype represents a realistic strategy for the rational identification and characterization of new potential therapeutic targets in an effort to improve the clinical management and the outcome of high-risk endometrial cancer patients.

GALR1 Methylation in Vaginal Swabs Is Highly Accurate in Identifying Women With Endometrial Cancer

GALR1 DNA methylation in vaginal swabs from women with postmenopausal bleeding indicates the presence of endometrial malignancy with a sensitivity of 92.7% and a specificity of 78.9%.
...

References

SHOWING 1-10 OF 20 REFERENCES

A Differential Gene Expression Profile Reveals Overexpression of RUNX1/AML1 in Invasive Endometrioid Carcinoma

Tissue array immunohistochemistry showed that RUNX1/AML1 up-regulation correlates to the process of tumorigenesis, from normal atrophic endometrium to simple and complex hyperplasia and then, on to carcinoma.

Molecular determinants of invasion in endometrial cancer

  • M. AbalM. Llauradó J. Reventós
  • Medicine
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • 2007
An overview of the molecular pathology of myometrial infiltration that defines the initial steps of invasion in endometrial cancer is presented.

A large-scale gene expression comparison of microdissected, small-sized endometrial cancers with or without hyperplasia matched to same-patient normal tissue.

  • Y. SugiyamaS. Dan T. Yamori
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
A more accurate way of assessing gene expression during endometrial carcinogenesis shows evidence of providing candidate genes for use in conquering endometrian carcinoma.

Subtractive proteomic approach to the endometrial carcinoma invasion front.

This work attempted an alternative proteomic approach to characterize specific components of the tumor invasive front or its reactive stroma, by comparing the invasive area of an endometrial carcinoma with the noninvasive superficial tumor area and normal tissue from the same patients.

Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer.

Gene expression differences in only 24 transcripts could distinguish serous from endometrioid cancers, the two most common subgroups, and provide the basis for investigation of previously unrecognized novel pathways involved in the development of endometrial cancers.

Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Endometrial carcinosarcoma is now considered a special, poor-prognosis subtype of endometrial carcinoma.

Should Preoperative Pathology Be Used to Select Patients for Surgical Staging in Endometrial Cancer?

Preoperative biopsy has only a moderate ability to predict final pathology in endometrial cancer, and therefore, additional factors should be considered in selecting patients for a surgical staging procedure.

An assessment of the value of ultrasonographic screening for endometrial disease in postmenopausal women without symptoms.

Despite a high negative predictive value, transvaginal ultrasonography may not be an effective screening procedure for detection of endometrial abnormality in untreated postmenopausal women who are without symptoms.

PET and PET–CT imaging of gynecological malignancies: present role and future promise

The modality appears to be of value in staging disease and is more effective than conventional diagnostic modalities with respect to detecting nodal metastasis in both malignancies.